IL6 and anemia: In our study, the chronic inflammation was indeed present in patients with chronic renal failure, accompanied by higher IL-6 levels, which can aggravate patients’ hyporesponsive to ESAs, but inflammation does not affect the efficacy of roxadustat in the treatment of anemia which consistent with previous studies (24, 25).